Routine TP53 testing for breast cancer under age 30: Ready for prime time?

Familial Cancer

Volumn 11, Issue 4, 2012, Pages 607-613

  McCuaig, Jeanna M ^a   Armel, Susan R ^a,b   Novokmet, Ana ^c   Ginsburg, Ophira M ^d   Demsky, Rochelle ^a   Narod, Steven A ^e   Malkin, David ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

BRCA; Breast cancer; Genetic testing; Hereditary; TP53

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53;

ADULT; BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMAN; MUTATIONAL ANALYSIS; ONSET AGE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCREENING TEST; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHILD; DIAGNOSTIC TESTS, ROUTINE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PEDIGREE; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84870410278     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-012-9557-z     Document Type: Review

References (33)

1. Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389-1399
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117-1130 (Pubitemid 36530000)
3. U.S. Preventive Services Task Force (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143(5):355-361
4. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury S, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-1089
5. Wu CC, Shete S, Amos CI, Strong LC (2006) Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res 66(16):8287-8292 (Pubitemid 44299199)
6. Wilson JRF, Bateman AC, Hanson H, An Q, Evans G, Rahman N et al (2010) A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 47:771-774
7. Amal Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM et al (2011) Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908-913
8. Li FP, Fraumeni JF Jr (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 71:747-752
9. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreygus MG, Tucker MA, Miller RW (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48(18):5358-5362
10. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54(5):1298-1304 (Pubitemid 24108072)
11. Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surv 25:101-124 (Pubitemid 26065308)
12. Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaíti- Pillié C, Stoppa-Lyonnet D, Frébourg T (2009) 2009 version of the Chompret criteria for Li-Fraumeni syndrome. J Clin Onco 27(26):e108-e109
13. Toronto Hospital for Sick Children (n.d.) Li-Fraumeni syndrome. In: Molecular genetics laboratory: test services available. 2011. [http://www.sickkids.ca/PaediatricLaboratoryMedicine/Laboratories-Services/ Molecular-Genetics-Laboratory/Test-Services-Available/Li-Fraumeni-Syndrome. html#3]
14. Lalloo F, Varley J, Ellis D, Moran A, O'Dair L, Pharoah P, Evans DG, Early Onset Breast Cancer Study Group (2003) Prediction of pathogenic mutations in patients with early-onset family history. Lancet 361(9363):1101-1102 (Pubitemid 36369565)
15. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12):1379-1388
16. Bougeard G, Sesboüé R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, Brugières L, Compret A, de Paillerets BB, Stoppa-Lyonnet D, Bonaíti-Pillié C, Frébourg T, French LFS working group (2008) Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45(8): 535-538
17. Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, Kluijt I, Siimons RH, Aalfs CW, Wagner A, Ausems MG, Hoogerbrugge N, van Asperen CJ, Gomez Garcia EB, Meihers-Heijboer H, Ten Kate LP, Menko FH, vańt Veer LJ (2010) TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47(6):421-428
18. Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, Ghadirian P, Robidoux A, Londono J, Vasquez G, Gomes M, Costa MM, Dimitrakakis C, Gutierrez G, Pilarski R, Royer R, Narod SA (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8(4): 563-567
19. Gonzalez KD, Noltner KA, Buszin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, Weitzel JN (2009) Beyond Li-Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250-1256
20. Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Gilies GG, Hopper JL, Southey MC (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 70(12):4795-4800
21. Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA (2000) Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88(6):1393-1402 (Pubitemid 30155177)
22. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310-2318 (Pubitemid 34441658)
23. Hansen TV, Bisgaard ML, Jønson L, Albrechtsen A, Filtenborg-Barnkob B, Eiberg H, Ejlertsen B, Nielsen FC (2008) Novel de novo BRCA2 mutation in a patient with a family history of breast cancer. BMC Med Genet 9:58
24. Marshall M, Solomon S, Lawrence Wickerham D (2009) Case report: de novo BRCA2 gene mutation in a 35-year-old woman with breast cancer. Clin Genet 76(5):427-430
25. Robson M, Scheuer L, Nafa K, Ellis N, Offit K (2002) Unique de novo mutation of BRCA2 in a woman with early onset breast cancer. J Med Genet 39(2):126-128 (Pubitemid 34146383)
26. Tesoriero A, Andersen C, Southey M, Somers F, McKay M, Armes J, McCredie M, Giles G, Hopper JL, Venter D (1999) De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet 65(2):567-569 (Pubitemid 30463015)
27. van der Luijt RB, van Zon PH, Jansen RP, van der Sijs-Bos CJ, Warlam-Rodenhuis CC, Ausems MG (2001) De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer. J Med Genet 38(2):102-105 (Pubitemid 32171342)
28. Edwards E, Yearwood C, Sillibourne J, Baralle D, Eccles D (2009) Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer. Fam Cancer 8(4):479-482
29. Gonzalez KD, Buzin CH, Noltner KAGuD, Li W, Malkin D, Sommer SS (2009) High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 46(10):689-693
30. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP (2001) Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 96(4):238-242 (Pubitemid 33081228)
31. Villani A, Tabori U, Schiffman J, Shlien A, Bevene J, Druker H, Novokmet A, Finlay J, Malkin D (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 12(6):559-567
32. Lee DSC, Yoon S, Looi LM, Kang P, Kang IN, Sivanandan K et al (2012) Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res 14:R66
33. Canadian Cancer Society's Steering Committee on Cancer Statistics (2011) Canadian cancer statistics 2011. Canadian Cancer Society, Toronto